Learn About Geographic Atrophy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Duke Health Integrated Practice Inc
Glenn Jaffe is an Ophthalmologist in Durham, North Carolina. Dr. Jaffe is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal. Dr. Jaffe is currently accepting new patients.
Vitreous Retina Macula Consultants Of New York(Downtown)
Richard Spaide is an Ophthalmologist in New York, New York. Dr. Spaide is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Central Serous Chorioretinopathy, Geographic Atrophy, and Vitrectomy.
Cynthia Toth is an Ophthalmologist in Durham, North Carolina. Dr. Toth is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. Her top areas of expertise are Retinopathy of Prematurity, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Corneal Transplant. Dr. Toth is currently accepting new patients.
Summary: Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration ABBV...
Summary: This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.